SLC5A2 and type 2 diabetes mellitus: Beyond the noticeable CV-beneficial effects of SGLT2-Is, reduced progression of chronic kidney disease was reported in T2DM patients along with an improvement of HF patients’ outcomes, regardless of diabetes, thus making it dutiful to include the use of gliflozins for these subsets of patients in the most recent guidelines [188,257].